new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc_20100128
Regeneron Pharmaceuticals Inc_20131212

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

  

Regeneron Pharmaceuticals Inc patents


      
Recent patent applications related to Regeneron Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc is listed as an Agent/Assignee. Note: Regeneron Pharmaceuticals Inc may have other listings under different names/spellings. We're not affiliated with Regeneron Pharmaceuticals Inc, we're just tracking patents.

ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "R" | Regeneron Pharmaceuticals Inc-related inventors




Count Application # Date Regeneron Pharmaceuticals Inc patents (updated weekly) - BOOKMARK this page
12016003059102/04/16 Biologically active molecules, conjugates thereof, and therapeutic uses
22016003201502/04/16 Stabilized formulations containing anti-pcsk9 antibodies
32016003353002/04/16 Isolating cells expressing secreted proteins
42016002185601/28/16 Genetically modified t cell receptor mice
52016002414701/28/16 Purification platform for bispecific antibodies
62016002419501/28/16 Human antibodies to grem1
72016002420801/28/16 Human antibodies to nav1.7
82016001702901/21/16 Stabilized formulations containing anti-ngf antibodies
92016000757901/14/16 Humanized dipeptidyl peptidase iv (dpp4) animals
102016000233201/07/16 Anti-asic1 antibodies and uses thereof
112016000234101/07/16 Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
122015037626712/31/15 Human antibodies to human delta like ligand 4
132015037626912/31/15 Human antibodies to serum resistance-associated protein from trypanosoma brucei rhodesiense
142015037662812/31/15 Nuclease-mediated dna assembly
152015037665012/31/15 Methods and compositions for modifying a targeted locus
162015037665112/31/15 Methods and compositions for targeted genetic modifications and methods of use
172015036617412/24/15 Non-human animals having a humanized programmed cell death 1 gene
182015036617512/24/15 Humanized il-15 animals
192015035137112/10/15 Hybrid light chain mice
202015035137212/10/15 Humanized dipeptidyl peptidase iv (dpp4) animals
212015035363412/10/15 Production cell line enhancers
222015034216312/03/15 Genetically modified major histocompatibility complex mice
232015033702911/26/15 Human antibodies to middle east respiratory syndrome - coronavirus spike protein
242015033704311/26/15 Anti-egfr antibodies and uses thereof
252015033704511/26/15 Human antibodies to the glucagon receptor
262015032752411/19/15 Genetically modified non-human animals expressing human epo
272015033099811/19/15 Vegf-a121 assay
282015033099911/19/15 Vegf-a121 assay
292015032002111/12/15 Humanized il-4 and il-4ra animals
302015032002211/12/15 Humanized il-4 and il-4ra animals
312015032002311/12/15 Human lambda light chain mice
322015031319311/05/15 Common light chain mouse
332015031319411/05/15 Humanized c5 and c3 animals
342015031319511/05/15 Low affinity fcgr deficient mice
352015029930310/22/15 Human antibodies to fel d1 and methods of use thereof
362015029930910/22/15 Production cell line enhancers
372015029931010/22/15 Production cell line enhancers
382015028948910/15/15 Non-human animals that make single domain binding proteins
392015029197810/15/15 Mirna-regulated differentiation-dependent self-deleting cassette
402015028246310/08/15 Non-human animals having humanized fc-gamma receptors
412015028447410/08/15 Anti-pcsk9 antibodies with ph-dependent binding characteristics
422015027209210/01/15 Humanized il-6 and il-6 receptor
432015026695709/24/15 Anti-prokineticin receptor (prokr) antibodies and uses thereof
442015026696609/24/15 Methods and antibody compositions for tumor treatment
452015026697609/24/15 Vl antigen binding proteins exhibiting distinct binding characteristics
462015025942309/17/15 Anti-egfrviii antibodies and uses thereof
472015025015109/10/15 Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
482015025210709/10/15 Aplnr modulators and uses thereof
492015024559809/03/15 Genetically modified major histocompatibility complex animals
502015024611909/03/15 Methods for treating or preventing asthma by administering an il-4r antagonist
512015024697309/03/15 Methods for treating skin infection by administering an il-4r antagonist
522015024697609/03/15 Hybrid light chain mice
532015024697709/03/15 Hybrid light chain mice
542015023123608/20/15 Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
552015023254508/20/15 Human antibodies to human delta like ligand 4
562015020862207/30/15 Genetically modified non-human animals and methods of use thereof
572015021077607/30/15 Adam6 mice
582015020158907/23/15 Adam6 mice
592015020357907/23/15 Human antibodies to pd-1
602015020358007/23/15 Human antibodies to pd-l1
612015020359107/23/15 Mutivalent antigen-binding proteins
622015019601507/16/15 Mice that make heavy chain antibodies
632015019755307/16/15 Mice that make heavy chain antibodies
642015019755407/16/15 Mice that make heavy chain antibodies
652015019755507/16/15 Mice that make heavy chain antibodies
662015019755607/16/15 Mice that make heavy chain antibodies
672015019755707/16/15 Mice that make heavy chain antibodies
682015019756407/16/15 Anti-angptl3 antibodies and uses thereof
692015019757807/16/15 Anti-tie2 antibodies and uses thereof
702015019153407/09/15 Human antibodies to human delta like ligand 4
712015017333106/25/15 Human lambda light chain mice
722015017333206/25/15 Human lambda light chain mice
732015017567606/25/15 Fusion polypeptides capable of activating receptors
742015017568806/25/15 Production cell line enhancers
752015017600206/25/15 Human lambda light chain mice
762015016559806/18/15 Devices and methods for facilitating treatment of electrospray columns
772015016664706/18/15 Antikine antibodies that bind to multiple cc chemokines
782015016021506/11/15 Isolating cells expressing secreted proteins
792015015217706/04/15 High affinity human antibodies to human angiopoietin-2
802015015219106/04/15 Dosing regimens for use with pcsk9 inhibitors
812015014734205/28/15 Methods for treating cancer by administering an anti-ang-2 antibody
822015014000205/21/15 Use of a pcsk9 inhibitor to treat hyperlipidemia
832015014355805/21/15 Non-human animals having a humanized b-cell activating factor gene
842015014355905/21/15 Non-human animals having a humanized a proliferation-inducing ligand gene
852015014356105/21/15 Non-human animals having a humanized b-cell activating factor gene
862015014356205/21/15 Non-human animals having a humanized a proliferation-inducing ligand gene
872015011955604/30/15 Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
882015011075404/23/15 High resolution allele identification
892015011080104/23/15 Human antibodies to gfr alpha 3 and methods of use thereof
902015010573504/16/15 Syringe pistons, systems and methods
912015010696104/16/15 Humanized il-15 animals
922015009929604/09/15 Promoter-regulated differentiation-dependent self-deleting cassette
932015010003004/09/15 Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
942015008967803/26/15 Non-human animals having a humanized signal-regulatory protein gene
952015008967903/26/15 Non-human animals having a humanized signal-regulatory protein gene
962015008968003/26/15 Human lambda light chain mice
972015007908703/19/15 Vegf antagonist formulations
982015008246903/19/15 Humanized il-7 rodents
992015006418903/05/15 Method of treating cancer with dll4 antagonist and chemotherapeutic agent
1002015006790103/05/15 Production of fertile xy female animals from xy es cells
1012015005622102/26/15 Anti-prlr antibodies and uses thereof
1022015005622202/26/15 Anti-prlr antibodies and uses thereof
1032015005900902/26/15 Methods for making fully human bispecific antibodies using a common light chain
1042015004706102/12/15 Humanized m-csf mice
1052015004706202/12/15 Lincrna-deficient non-human animals
1062015003733902/05/15 Anti-activin a antibodies and uses thereof
1072015004025302/05/15 Genetically modified major histocompatibility complex mice
1082015002441201/22/15 Humanized fcgammar mice
1092015001717601/15/15 Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
1102015001718201/15/15 Methods for treating nasal polyposis by administering an il-4r antagonist
1112015002022401/15/15 Non-human animals with modified immunoglobulin heavy chain sequences
1122015001056801/08/15 Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a
1132015001302201/08/15 Humanized il-6 and il-6 receptor
1142015001302301/08/15 Humanized il-6 and il-6 receptor
1152014035637012/04/14 Methods for treating autosomal dominant hypercholesterolemia associated with pcsk9 gain-of-function mutations
1162014035637112/04/14 Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
1172014035637212/04/14 Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
1182014033134011/06/14 Methods and compositions for generating a mouse
1192014032221510/30/14 Methods of inhibiting tumor growth by antagonizing il-6 receptor
1202014031524910/23/14 Inducible eukaryotic expression system
1212014028987609/25/14 Mice that make heavy chain antibodies
1222014027164209/18/14 Il-33 antagonists and uses thereof
1232014027165309/18/14 Human antibodies to respiratory syncytial virus f protein and methods of use thereof
1242014027165809/18/14 Anti-il-33 antibodies and uses thereof
1252014027168109/18/14 High affinity human antibodies to human il-4 receptor
1262014027309509/18/14 Serum-free cell culture medium
1272014027548909/18/14 Apelin fusion proteins and uses thereof
1282014028315809/18/14 Rodents with conditional acvr1 mutant alleles
1292014025539009/11/14 Method of treating rheumatoid arthritis with an anti-il-6r antibody
1302014025541909/11/14 Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
1312014025542909/11/14 Methods of treating autoimmune diseases with dll4 antagonists
1322014025599509/11/14 High affinity antibodies to human il-6 receptor
1332014024866409/04/14 Readily isolated bispecific antibodies with native immunoglobulin format
1342014024350408/28/14 Antibodies comprising chimeric constant domains
1352014024546608/28/14 Humanized t cell co-receptor mice
1362014024546708/28/14 Genetically modified major histocompatibility complex mice
1372014024546808/28/14 Non-human animals with modified immunoglobulin heavy chain sequences
1382014022002308/07/14 Method of treating osteoarthritis with an antibody to ngf
1392014021377307/31/14 Adam6 mice
1402014019655007/17/14 Systems and devices for sample handling
1412014019976107/17/14 Promoter-regulated differentiation-dependent self-deleting cassette
1422014019340207/10/14 Anti-pdgfr-beta antibodies and uses thereof
1432014019459707/10/14 Modified chimeric polypeptides with improved pharmacokinetic properties
1442014018990007/03/14 Mirna-regulated differentiation-dependent self-deleting cassette
1452014017887906/26/14 Compositions and methods for modifying cells
1462014017990306/26/14 High affinity human antibodies to human protease-activated receptor 2
1472014015470106/05/14 Humanized fc gamma r mice
1482014015568906/05/14 Methods of modifying genes in eukaryotic cells
1492014015744506/05/14 Low affinity fcgr deficient mice
1502014013797805/22/14 System and methods for use in dispensing biopharmaceutical materials
1512014013416905/15/14 Methods of treating ovarian cancer with dll4 antagonists
1522014013418905/15/14 Anti-prokineticin receptor (prokr) antibodies and uses thereof
1532014013471905/15/14 Recombinant cell surface capture proteins
1542014013727505/15/14 Hybrid light chain mice
1552014013019305/08/14 Mice that make vl binding proteins
1562014013019405/08/14 Mice that make vl binding proteins
1572014012010905/01/14 Human antibodies to human tnf-like ligand 1a (tl1a)
1582014011293004/24/14 Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
1592014009931204/10/14 Methods for treating hypercholesterolemia and reducing ldl-c using antibodies to pcsk9
1602014008829503/27/14 Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
1612014008276003/20/14 Non-human animals expressing ph-sensitive immunoglobulin sequences
1622014007256303/13/14 Methods and compositions comprising a combination of an anti-erbb3 antibody and an anti-egfr antibody
1632014007258303/13/14 Methods for treating atopic dermatitis by administering an il-4r antagonist
1642014007297903/13/14 Isolating cells expressing secreted proteins
1652014007298003/13/14 Isolating cells expressing secreted proteins
1662014007301003/13/14 Methods of modifying eukaryotic cells
1672014007558603/13/14 Parental cell lines for making cassette-free f1 progeny
1682014005690302/27/14 Human antibodies to gfr alpha 3 and methods of use thereof
1692014005690702/27/14 Anti-asic1 antibodies and uses thereof
1702014004473002/13/14 Anti-pcsk9 antibodies with ph-dependent binding characteristics
1712014004106802/06/14 Methods of modifying eukaryotic cells
1722014003333601/30/14 Methods of modifying eukaryotic cells
1732014003333701/30/14 Methods of modifying eukaryotic cells
1742014002363701/23/14 Methods of modifying eukaryotic cells
1752014001722801/16/14 Humanized light chain mice
1762014001722901/16/14 Methods of modifying eukaryotic cells
1772014001723801/16/14 Methods of modifying eukaryotic cells
1782014001769501/16/14 Isolating cells expressing secreted proteins
1792014001778101/16/14 Methods of modifying eukaryotic cells
1802014001778201/16/14 Methods for modifying eukaryotic cells
1812014001852201/16/14 Methods of modifying eukaryotic cells
1822014002012401/16/14 Methods of modifying eukaryotic cells
1832014002012501/16/14 Methods of modifying eukaryotic cells
1842014001345601/09/14 Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
1852014001345701/09/14 Methods of modifying eukaryotic cells
1862013034453812/26/13 Human antibodies to the glucagon receptor
1872013034010412/19/13 Humanized il-7 rodents
1882013033305712/12/13 Humanized non-human animals with restricted immunoglobulin heavy chain loci
1892013032326012/05/13 Stabilized formulations containing anti-dll4 antibodies
1902013032326112/05/13 Purified antibody composition
1912013032378812/05/13 Production cell line enhancers
1922013032379012/05/13 Human lambda light chain mice
1932013032379112/05/13 Restricted immunoglobulin heavy chain mice
1942013032664712/05/13 Human lambda light chain mice
1952013030967011/21/13 Nuclease-mediated targeting with large targeting vectors
1962013031212811/21/13 Promoter-regulated differentiation-dependent self-deleting cassette
1972013031212911/21/13 Promoter-regulated differentiation-dependent self-deleting cassette
1982013029509711/07/13 Human antibodies to fel d1 and methods of use thereof
1992013028075810/24/13 Fusion polypeptides capable of activating receptors
2002013027307010/17/13 Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor
2012013026657410/10/13 Human antibodies to human angiopoietin-like protein 4
2022013025987610/03/13 Anti-hla-b*27 antibodies and uses thereof
2032013025988110/03/13 Fusion polypeptides capable of activating receptors
2042013026105610/03/13 Vegf antagonist formulations
2052013025172809/26/13 Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
2062013025491109/26/13 Adam6 mice
2072013024377509/19/13 Multispecific antigen-binding molecules and uses thereof
2082013024378409/19/13 Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
2092013024723409/19/13 Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
2102013024723509/19/13 Mice that produce antigen-binding proteins with ph-dependent binding characteristics
2112013024723609/19/13 Non-human animals expressing ph-sensitive immunoglobulin sequences
2122013023053109/05/13 Human antibodies to clostridium difficile toxins
2132013023053309/05/13 Methods of treating systemic lupus erythematosus (sle) using anti-cd48 antibodies
2142013021654708/22/13 Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
2152013020949208/15/13 Anti-tie2 antibodies and uses thereof
2162013021013708/15/13 Methods of modifying eukaryotic cells
2172013021271908/15/13 Humanized rodents that express heavy chain containing vl domains
2182013019587808/01/13 Anti-asic1 antibodies and uses thereof
2192013019887908/01/13 Humanized universal light chain mice
2202013019888008/01/13 Mice expressing a limited immunoglobulin light chain repertoire
2212013018679707/25/13 Stabilized formulations containing anti-ang2 antibodies
2222013018927707/25/13 Stabilized formulations containing anti-pcsk9 antibodies
2232013018420507/18/13 Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof
2242013018581907/18/13 Genetically modified major histocompatibility complex animals
2252013018582007/18/13 Genetically modified major histocompatibility complex animals
2262013018582107/18/13 Common light chain mouse
2272013017114907/04/13 Anti-angptl3 antibodies and uses thereof
2282013016478606/27/13 Fucosylation-deficient cells
2292013015731306/20/13 High affinity antibodies to human il-6 receptor
2302013016015306/20/13 Humanized light chain mice
2312013014974406/13/13 Methods for producing a fusion protein capable of binding vegf
2322013013710105/30/13 Methods of modifying eukaryotic cells
2332013012972205/23/13 Methods for treating cancer by administering an anti-ang-2 antibody
2342013012983005/23/13 Polymer protein microparticles
2352013013037205/23/13 Enhanced expression and stability regions
2362013013038805/23/13 Methods of modifying eurakyotic cells
2372013012200305/16/13 Methods of inhibiting tumor growth by antagonizing il-6 receptor
2382013012200705/16/13 Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a
2392013011787305/09/13 Humanized il-6 and il-6 receptor
2402013010905305/02/13 Genetically modified t cell receptor mice
2412013011161605/02/13 Genetically modified major histocompatibility complex mice
2422013011161705/02/13 Genetically modified major histocompatibility complex mice
2432013009556504/18/13 Mirna-regulated differentiation-dependent self-deleting cassette
2442013009628704/18/13 Restricted immunoglobulin heavy chain mice
2452013008429704/04/13 Anti-erbb3 antibodies and uses thereof
2462013008463504/04/13 Cell culture compositions capable of producing a vegf-binding fusion polypeptide
2472013008526604/04/13 Anti-pcsk9 antibodies with ph-dependent binding characteristics
2482013007867503/28/13 High affinity human antibodies to human il-4 receptor
2492013006483403/14/13 Methods for treating hypercholesterolemia using antibodies to pcsk9



ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Regeneron Pharmaceuticals Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Regeneron Pharmaceuticals Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###